Organogenesis Holdings Inc. (NASDAQ: ORGO) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $105M. The Maz Rating grades it against the other companies in its sector.
Organogenesis Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.81, Organogenesis Holdings Inc. trades at 0.3x sales and 0.9x book value. Over the last twelve months it generated about $351M of revenue and a net loss of $153M. It runs a gross margin of 62.0%, an operating margin of -22.8% and a net margin of -40.2%. It shows return on equity of -46.3%, return on invested capital of -24.3% and a free cash flow yield of -0.1%. On the balance sheet: a debt-to-equity ratio of 0.54 and a current ratio of 3.32. Over the past 52 weeks the share price ranged from $0.73 to $5.99, with a beta of 1.27.
Organogenesis Holdings Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Organogenesis Holdings Inc. (ORGO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, MSCI and FTSE, and fails S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.8% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.8% / 33% · Receivables / Mkt Cap (36m) 55.7% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.8% / 33.33% · Receivables / Mkt Cap (24m) 55.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 13.4% / 33.33% · Receivables / Avg Assets (4Q) 27.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 5.78% / 33.33% · (Cash+Recv) / Total Assets 30.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Organogenesis Holdings Inc. (ORGO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, MSCI and FTSE, and fails S&P Global and Dow Jones.
Yes. Organogenesis Holdings Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Organogenesis Holdings Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.